Inclusion Criteria:

          -  1 Patients with recurrent or progressive glioblastoma or other grade IV malignant
             glioma (i.e. glioblastoma, gliosarcoma, giant cell glioblastoma, etc.) who have failed
             prior radiation but who have not progressed/recurred on bevacizumab. Patients will be
             eligible if the original histology was lower-grade glioma and subsequent diagnosis of
             glioblastoma or gliosarcoma is made.

             2 Patients with any number of recurrences are allowed. 3 Brain MRI demonstrates an
             enhancing tumor < 8 cm in largest diameter. 4 Karnofsky performance status ≥ 70%. 5
             Age ≥ 22 years old. 6 Patients must have the following laboratory values:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  Platelets ≥ 100 x 109/L

               -  Hemoglobin (Hgb) > 10 g/dL

               -  Serum total bilirubin: ≤ 1.5 x ULN

               -  ALT and AST ≤ 3.0 x ULN

               -  Adequate Renal Function: BUN and Cr < 2.0 x ULN

               -  Blood coagulation parameters: international normalized ratio (INR) ≤ 1.5 for
                  patients not on warfarin 7 Minimum interval since completion of radiation
                  treatment is 12 weeks. 8 History of standard dose CNS radiotherapy: radiation of
                  60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower
                  doses.

                  9 Minimum interval since last major surgery, open biopsy, or significant
                  traumatic injury is 4 weeks 10 Minimum interval since last drug therapy:

               -  3 weeks since last non-cytotoxic therapy

               -  3 weeks must have elapsed since the completion of a non-nitrosourea-containing
                  chemotherapy regimen

               -  6 weeks since the completion of a nitrosourea-containing chemotherapy regimen. 11
                  Patients must have signed an approved informed consent and authorization
                  permitting release of personal health information.

                  12 Patients with the potential for pregnancy or impregnating their partner must
                  agree to follow acceptable birth control methods to avoid conception. Female
                  patients of child-bearing potential must have a negative pregnancy test.

                  13 Patients with history of prior invasive malignancy (except non-melanomatous
                  skin cancer) must have been disease free for a minimum of 1 year.

                  14 Patients must be maintained on a stable corticosteroid regimen from the time
                  of their baseline scan until the start of treatment and/or for at least 5 days
                  before starting treatment.

                  15 Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet
                  both of the following criteria: 16 No active bleeding or pathological condition
                  that carries a high risk of bleeding (e.g., tumor involving major vessels or
                  known varices) 17 In-range INR (max ≤ 3) on a stable dose of oral anticoagulant
                  for greater than 1 month or on a stable dose of low molecular weight heparin

        Exclusion Criteria:

          -  1 Any prior therapy with bevacizumab 2 Any significant hemorrhage defined as > 1 cm
             diameter of blood seen on the MRI or CT scan. If > 1 cm of acute blood is detected,
             the patient will be ineligible for this trial.

             3 Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
             intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting
             study drug, or patients who have had minor procedures, percutaneous biopsies or
             placement of vascular access device ≤ 1 week prior to starting study drug, or who have
             not recovered from side effects of such procedure or injury.

             4 Patients with impaired cardiac function or clinically significant cardiac diseases,
             including any of the following:

               -  History or presence of serious uncontrolled ventricular arrhythmias

               -  Any of the following within 6 months prior to starting study drug: myocardial
                  infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG),
                  Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient
                  Ischemic Attack (TIA), Pulmonary Embolism (PE)

               -  Uncontrolled hypertension (defined by a SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg while
                  on anti-hypertensive medications) or history of hypertensive crisis or
                  hypertensive encephalopathy, stroke, TIA, symptomatic peripheral vascular
                  disease, or grade 2 CHF 5 Patients with cirrhosis, or active viral or non-viral
                  hepatitis. 6 Patients with peptic ulcer, abdominal fistula, gastrointestinal
                  perforation, intra-abdominal abscess within 6 months of enrollment.

                  7 Implanted pacemaker, defibrillator or deep brain stimulator, other implanted
                  electronic devices in the brain or documented clinically significant arrhythmias.

                  8 Infra-tentorial tumor. 9 Known sensitivity to conductive hydrogels. 10 Known
                  diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
                  mandatory).

                  11 Other concurrent severe and/or uncontrolled concomitant medical conditions
                  (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause
                  unacceptable safety risks or compromise compliance with the protocol 12 Pregnant
                  or breast-feeding women. 13 Patients unwilling or unable to comply with the
                  protocol. 14 Patients treated on any other therapeutic clinical protocols within
                  3 weeks of starting on this study.